Puma Biotechnology, Inc.(NASDAQ : PBYI)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-1.33%||159.75||0.7%||$1251.42m|
|LLY||Eli Lilly & Co.||-1.66%||327.41||1.1%||$1087.67m|
|BMY||Bristol-Myers Squibb Co.||-0.54%||69.86||1.0%||$747.73m|
|MRK||Merck & Co., Inc.||-0.14%||87.32||0.7%||$696.69m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-2.13%||198.06||8.2%||$220.04m|
|HZNP||Horizon Therapeutics Plc||-3.51%||65.51||5.4%||$182.09m|
|GBT||Global Blood Therapeutics, Inc.||0.00%||68.49||5.4%||$178.81m|
|IDXX||IDEXX Laboratories, Inc.||-3.56%||333.72||3.9%||$177.78m|
|SRPT||Sarepta Therapeutics, Inc.||-2.42%||112.04||12.4%||$138.30m|
|AKRO||Akero Therapeutics, Inc.||-1.48%||38.68||0.0%||$132.19m|
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.